Forwarded from Patriot Politics Research☦🇺🇸🦅 (Patriot Politics Research)
* 🚨 FDA DIDN'T "REFER" TO VRBPAC 🚨 *
• Page 2:
"You may label your product with the proprietary name, COMIRNATY, and market it in 2.0 mL glass vials, in packages of 25 and 195 vials. We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion."
• COMIRNATY Approval Letter Link:
https://www.fda.gov/media/151710/download
#Comirnaty #RecallVaccines #Vaccines #COVID19
• Page 2:
"You may label your product with the proprietary name, COMIRNATY, and market it in 2.0 mL glass vials, in packages of 25 and 195 vials. We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion."
• COMIRNATY Approval Letter Link:
https://www.fda.gov/media/151710/download
#Comirnaty #RecallVaccines #Vaccines #COVID19
Forwarded from Patriot Politics Research☦🇺🇸🦅 (Patriot Politics Research)
*🚨 FDA Approval Letter: Investigation - continued*
Does this sound logical or illogical?
• Page 4:
"We are deferring submission of your pediatric studies for ages younger than 16 years for this application because this product is ready for approval for use in individuals 16 years of age and older, and the pediatric studies for younger ages have not been completed."
• DEFER?!
• Like how on Earth does that make any sense?
• Any and all children affected from "COMIRNATY" will not be able to DEFER their permanent side effects nor other side effects such as death...
• FDA Approval Letter PDF Link:
https://www.fda.gov/media/151710/download
#COMIRNATY #COVID19 #VACCINES #RecallVaccines
Does this sound logical or illogical?
• Page 4:
"We are deferring submission of your pediatric studies for ages younger than 16 years for this application because this product is ready for approval for use in individuals 16 years of age and older, and the pediatric studies for younger ages have not been completed."
• DEFER?!
• Like how on Earth does that make any sense?
• Any and all children affected from "COMIRNATY" will not be able to DEFER their permanent side effects nor other side effects such as death...
• FDA Approval Letter PDF Link:
https://www.fda.gov/media/151710/download
#COMIRNATY #COVID19 #VACCINES #RecallVaccines
Forwarded from Patriot Politics Research☦🇺🇸🦅 (Patriot Politics Research)
• COMIRNATY was FDA BLA approved on August 23, 2021.
• As of August 27, 2021:
- Pfizer-BioNTech Vaccine-Related Deaths: 9,467
• 08/20/21: 9,467
• 08/13/21: 9,024
• Difference: 443 more Pfizer-BioNTech/COMIRNATY Vaccine-Related Deaths
#VAERS #VaccineDeaths #PfizerBioNTech #COMIRNATY #RecallVaccines #FDA
• As of August 27, 2021:
- Pfizer-BioNTech Vaccine-Related Deaths: 9,467
• 08/20/21: 9,467
• 08/13/21: 9,024
• Difference: 443 more Pfizer-BioNTech/COMIRNATY Vaccine-Related Deaths
#VAERS #VaccineDeaths #PfizerBioNTech #COMIRNATY #RecallVaccines #FDA
Forwarded from Patriot Politics Research☦🇺🇸🦅 (Patriot Politics Research)
* 🚨 FDA DIDN'T "REFER" TO VRBPAC 🚨 *
• Page 2:
"You may label your product with the proprietary name, COMIRNATY, and market it in 2.0 mL glass vials, in packages of 25 and 195 vials. We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion."
• COMIRNATY Approval Letter Link:
https://www.fda.gov/media/151710/download
#Comirnaty #RecallVaccines #Vaccines #COVID19
• Page 2:
"You may label your product with the proprietary name, COMIRNATY, and market it in 2.0 mL glass vials, in packages of 25 and 195 vials. We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion."
• COMIRNATY Approval Letter Link:
https://www.fda.gov/media/151710/download
#Comirnaty #RecallVaccines #Vaccines #COVID19